Pharmaceutical Strategy: Novel Antibacterial Drug Development Plan

This report outlines a strategy for a pharmaceutical company to develop a novel antibacterial drug, focusing on Mycobacterium tuberculosis (MTB) and multiple drug resistant tuberculosis (MDR-TB). It proposes targeting the central bacteria metabolism system, using high throughput chemical screening, and a preclinical development phase that includes pharmacokinetics, pharmacodynamics, and toxicology testing. The strategy aims to address the high costs, lengthy timelines, and scientific challenges associated with antibacterial drug development, providing a viable path for resource allocation and successful drug discovery.

Running head: BIOLOGICAL SCIENCES
DRUG DEVELOPMENT ASSIGNMENT
Name of the Student
Name of the University
Author note

1BIOLOGICAL SCIENCES
Bacterial Disease
Infection to Mycobacterium tuberculosis or MTB is one of the primary reasons for
morbidity and mortality for the people of low-middle income countries because of increased
resistance and hence, drug development against such resistance strains becomes one of the
primary sources using which such disease could be treated (Coll et al. 2015). Hence,
Tuberculosis, especially the multiple drug resistant tuberculosis (MDR-TB) will be chosen as the
disease for drug development assignment.
Source of Chemical Matter
To treat MDR-TB, the target for the antibiotic should be the central bacteria metabolism
system as this area of the drug discovery has very less amount of research and proposals. Success
achieved in targeting bacterial central metabolism would emerge as a big discovery for the drugs
associated to MDR-TB. Further, the chemical compound targeting the central metabolism of
bacteria would be able to deplete the non-fermentable carbon source so that it could not use the
non-fermentable carbon as the source. Therefore, this pathway will be chosen for this drug
discovery (Murima, McKinney and Pethe 2014).
Screening Approach
High throughput chemical screening process will be used in the screening process of
the new drug as it interacts with the bacterial influx system and it would be easier to
understand the effectiveness of the source used, to affect the bacterial metabolism system.
Therefore, this method of screen would be used to conduct the screening (Murima, McKinney
and Pethe 2014).

2BIOLOGICAL SCIENCES
Pre-Clinical Development
The preclinical developmental stage of the new drug will start depending on its safety
level, its effect on genetic level, and diagnostic tools in any adverse condition. This will hence,
be inclusive of pharmacokinetics, pharmacodynamics and toxicology testing of the drug. After
that the drug development will focus on the effect of the drug on animal samples and if found
safe and effective the action of human tissue culture will be determined (Farha and Brown 2016).

3BIOLOGICAL SCIENCES
References
Coll, F., McNerney, R., Preston, M.D., Guerra-Assunção, J.A., Warry, A., Hill-Cawthorne, G.,
Mallard, K., Nair, M., Miranda, A., Alves, A. and Perdigão, J., 2015. Rapid determination of
anti-tuberculosis drug resistance from whole-genome sequences. Genome medicine, 7(1), p.51.
Farha, M.A. and Brown, E.D., 2016. Strategies for target identification of antimicrobial natural
products. Natural product reports, 33(5), pp.668-680.
Murima, P., McKinney, J.D. and Pethe, K., 2014. Targeting bacterial central metabolism for
drug development. Chemistry & biology, 21(11), pp.1423-1432.